Davis Gregory D 4

What Happened
Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), received a grant of 225,000 derivative securities on April 1, 2026. The Form 4 reports an acquisition price of $0.00 (total reported cash value $0). This is a compensation award (derivative/option grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-01; filing date: 2026-04-03 (appears timely).
• Transaction type: Award/Grant of derivative securities (code A).
• Amount: 225,000 shares (derivative); price reported $0.00.
• Shares owned after transaction: not specified in the provided filing data.
• Footnote: Vesting schedule — 25% vests on the first anniversary of the grant, then the remaining shares vest in 24 equal monthly installments thereafter, subject to continuous service and any acceleration provisions under the 2018 EIP.
• Filing does not indicate a 10b5-1 plan, tax withholding, or immediate sale.

Context
This was a compensation grant (an option-like derivative award) rather than a buy or sell. Such grants are common for executives and often vest over time to retain and incentivize employees; they do not, by themselves, signal insider buying or selling intent. The footnote confirms a multi-year vesting schedule, so the award will convert into exercisable rights over time subject to continued service.